MACH is delighted to welcome Professor Shelley Dolan, CEO of the Peter MacCallum Cancer Centre and incoming CEO of The Royal Melbourne Hospital (RMH), to the MACH Board from June 21. 

Professor Dolan succeeds outgoing RMH CEO, Professor Christine Kilpatrick AO, after five years of service on the MACH Board and six years of outstanding leadership at one of the largest health providers in Australia.

Professor Jane Gunn, Chair of the MACH Board, says she is delighted to welcome Professor Dolan to the MACH Board representing health service partners together with Adjunct Professor Russell Harrison, CEO of Western Health.

“I’m looking forward to the contribution Professor Dolan will make, as a leader whose experience spans research, health system reform and healthcare leadership.

“I would also like to thank Professor Kilpatrick for her outstanding, dedicated service and wish her the very best in her next exciting challenge.”

Professor Dolan brings more than 25 years’ Executive and Non-Executive Board experience to MACH.

“It’s a privilege to be joining Professor Gunn and the other Board Members,” Professor Dolan says.

“MACH does incredibly important work that brings together so many healthcare providers, researchers and universities.

“This collaboration has never been more critical, and I look forward to being part of this really important collaboration all focused on improving outcomes for patients,” she says.

Professor Dolan is a Professor (Enterprise) at the University of Melbourne’s School of Health Sciences with a PhD in the early diagnosis of sepsis in cancer patients and a Master’s degree in cancer nursing.

She also Chairs the Western and Central Melbourne Integrated Cancer Service and was appointed as a Member of the Cancer Australia Advisory Council in late 2022.

Professor Dolan was appointed Chief Executive of the Peter MacCallum Cancer in 2019 having previously held senior leadership roles at King’s College Hospital NHS Foundation Trust and the Royal Marsden NHS Foundation Trust. She will commence her role as RMH CEO on June 30.

We look forward to Professor Dolan’s valuable contribution to the MACH Board.